
Gareth J. Morgan, MD, PhD, discusses differences in low- and high-risk multiple myeloma.

Your AI-Trained Oncology Knowledge Connection!


Gareth J. Morgan, MD, PhD, discusses differences in low- and high-risk multiple myeloma.

Gareth J. Morgan, MD, PhD, discusses optimizing treatments for patients with ultra high–risk multiple myeloma.

Gareth J. Morgan, MD, PhD, discusses the evolution of treatment options in multiple myeloma.

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Gareth J. Morgan, MD, PhD, discusses research examining idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Gareth J. Morgan, MD, PhD, discusses the role of venetoclax in treating patients with multiple myeloma.

Gareth J. Morgan, MD, PhD, a professor in the Department of Medicine and director of Multiple Myeloma Research, NYU Langone Health’s Perlmutter Cancer Center, discusses BCMA-targeted antibody-drug conjugates (ADCs) in multiple myeloma.

Published: August 2nd 2021 | Updated:

Published: April 14th 2020 | Updated:

Published: April 17th 2020 | Updated:

Published: May 22nd 2020 | Updated:

Published: May 27th 2021 | Updated:

Published: March 18th 2020 | Updated: